Kawabe Kentaro, Horiuchi Fumie, Ochi Marina, Nishimoto Kayoko, Ueno Shu-Ichi, Oka Yasunori
1 Center for Child Health, Behavior and Development, Ehime University Hospital, Toon, Japan .
2 Department of Neuropsychiatry, Ehime University Graduate School of Medicine, Toon, Japan .
J Child Adolesc Psychopharmacol. 2017 Nov;27(9):792-795. doi: 10.1089/cap.2016.0206. Epub 2017 May 18.
Suvorexant is the first dual orexin receptor antagonist for treating insomnia. This study aimed to evaluate the tolerability, efficacy, and safety of suvorexant on insomnia in adolescents.
Thirty patients (8 male and 22 female; mean standard deviation age: 15.7 ± 2.4 years; range: 10-20) with insomnia were administered suvorexant. Clinical background, persistence rate, the Clinical Global Impression (CGI), and the Athens Insomnia Scale (AIS) were compared between patients who continued and discontinued suvorexant treatment.
Seventeen patients (56.7%) successfully continued taking suvorexant. Among the 13 patients who did not continue treatment, 5 patients were lost to follow-up. Of the remaining eight who did not continue treatment, four decided to discontinue of their own accord, two decided to discontinue due to lack of effectiveness, and two decided to discontinue due to adverse reaction, namely abnormal dreams. Among patients who completed the study, CGI significantly decreased from 3.6 ± 0.8 to 3.1 ± 0.9 (p = 0.014). The score of sleep quality in AIS was significantly higher among the patients who discontinued suvorexant than those who continued suvorexant (p = 0.02).
Our results indicate that suvorexant could be considered a treatment option for adolescents.
苏沃雷生是首个用于治疗失眠的双重食欲素受体拮抗剂。本研究旨在评估苏沃雷生治疗青少年失眠的耐受性、疗效和安全性。
30例失眠患者（8例男性，22例女性；平均标准差年龄：15.7±2.4岁；范围：10 - 20岁）接受了苏沃雷生治疗。对继续和停止苏沃雷生治疗的患者的临床背景、持续率、临床总体印象量表（CGI）和雅典失眠量表（AIS）进行了比较。
17例患者（56.7%）成功继续服用苏沃雷生。在未继续治疗的13例患者中，5例失访。在其余未继续治疗的8例患者中，4例自行决定停药，2例因无效决定停药，2例因不良反应即异常梦境决定停药。在完成研究的患者中，CGI从3.6±0.8显著降至3.1±0.9（p = 0.014）。停止服用苏沃雷生的患者的AIS睡眠质量得分显著高于继续服用苏沃雷生的患者（p = 0.02）。
我们的结果表明，苏沃雷生可被视为青少年失眠的一种治疗选择。
